Pulmonary Arterial Hypertension (PAH) Market Size Anticipated to Reach $8.7 Billion by 2025 | Million Insights

Pulmonary Arterial Hypertension (PAH) Market Size Anticipated to Reach $8.7 Billion by 2025 | Million Insights

PR Newswire

FELTON, California, April 10, 2018

FELTON, California, April 10, 2018 /PRNewswire/ --

The global Pulmonary Arterial Hypertension (PAH) Market size was valued at USD 5.0 billion in 2015 and is anticipated to reach USD 8.7 billion by 2025. Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. These arteries are called pulmonary arteries. PAH occurs when the pulmonary arteries thicken or grow rigid. PAH is one of the five groups of pulmonary hypertension, classified by the World Health Organization (WHO).

The market for PAH is growing moderately due to newer launches of pipeline drugs that target different pathways to suppress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in number of patients undergoing treatment.

Globally the PAH market is segmented on the basis of Drug class, Surgery, and region. On the basis of Drug class, the global PAH market is classified into Endothelin Receptor Antagonists (ERAs) (Tracleer, Opsumit, Letairis)- These medications reverse the effect of endothelin, a substance in the walls of blood vessels that causes them to narrow; Prostacyclin and Prostacyclin Analogs- were the first medications approved by the U.S. FDA for the treatment of PAH. Phosphodiesterase-5 (PDE-5) V Inhibitors, Sildenafil, and Tadalafil- Revatio, Viagra, Cialis, etc. These drugs work by opening the blood vessels in the lungs to allow blood to flow easily. These drugs have superiority over existing therapy options with respect to the therapeutic efficacy, route of administration, and side-effects.

A new drug called Uptravi (selexipag), which is a selective IP prostacyclin receptor agonist, is expected to be launched in 2016 and is likely to drive growth of the prostacyclin and prostacyclin analogs market. The rising sales of these newly-approved therapeutic agents are likely to contribute to the overall revenue of the market.

Browse 90 page research report with TOC on "Global Pulmonary Arterial Hypertension (PAH) Market" at: https://www.millioninsights.com/industry-reports/pulmonary-arterial-hypertension-pah-market 

Globally, regulatory bodies have granted an Orphan Drug Designation (ODD) status to all those drugs intended to diagnose and treat or cure a rare disease. In the U.S., the Orphan Drug Act (ODA) encourages pharmaceutical industries to develop orphan drugs by offering benefits such as tax credits, research grants, and orphan drug exclusivity of seven years. These benefits are escalating the development, manufacturing, and marketing of drugs intended to treat PAH, thereby driving market growth.

On the basis of surgeries, the global PAH market is classified into Atrial Septostomy- This is an open heart surgery; in which surgeon will create an opening between the upper left and right chambers of your heart to relieve the pressure on the right side of heart. Transplantation- Lung or heart-lung transplant might be an option especially for younger people who have idiopathic pulmonary arterial hypertension.

Geographically, PAH market is segmented into North America, Europe, Asia Pacific, Latin America, MEA, and Rest of the World. North America held the maximum share of market for PAH in terms of revenue in 2013, which is then followed by Europe. These two developed regions are expected to witness substantial growth during the forecast period, due to the recently approved PAH drugs in the market and the products that are anticipated to receive approval during the next few years. In the Asia Pacific region, Japan, China, India, Australia, and New Zealand exhibit immense opportunities for the companies operating in the PAH market.

The low level of awareness regarding the diagnosis and treatment of PAH is one of the prime reasons restraining the market growth in MEA and rest of the world. The patent expirations of major PAH drugs along with the availability of generic drugs are expected to adversely affect the overall revenue of the market. Some of the major players in the market are Actelion Pharmaceuticals, Ltd., Bayer HealthCare, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc. and United Therapeutics Corporation are the key players operating in the global PAH market.

Browse reports of similar category available with Million Insights: 

Global PAH Drug Class Outlook (Revenue, USD Million, 2014 - 2025) 

    • Prostacyclin and Prostacyclin Analogs

    • SGC Stimulators

    • ERA

    • PDE-5

PAH Regional Outlook (Revenue, USD Million, 2014 - 2025) 

    • North America

        • U.S.

        • Canada

    • Europe

        • UK

        • Germany

    • Asia Pacific

        • Japan

        • China

    • Latin America

        • Brazil

        • Mexico

    • MEA

        • South Africa

About Million Insights: 

Million Insights, is a distributor of market research reports, published by premium publishers only. We have a comprehensive market place, that will enable you to compare data points, before you make a purchase. Enabling informed buying, is our motto and we strive hard to ensure that our clients get to browse through multiple samples, prior to an investment. Service flexibility & the fastest response time are two pillars, on which our business model is founded. Our market research report store, includes in-depth reports, from across various industry verticals, such as healthcare, technology, chemicals, food & beverages, consumer goods, material science & automotive.

Contact:
Ryan Manuel
Research Support Specialist, USA
Million Insights
Phone: +1-408-610-2300
Toll Free: 1-866-831-4085
Email: sales@millioninsights.com

Web: https://www.millioninsights.com/

Voltar noticias em Inglês